NASDAQ · Biotechnology

DARE (DARE) Stock

$1.32 +3.13% NASDAQ: DARE Healthcare

Valuation

MetricValue
Price$1.32
Market Cap$12.57M
P/E Ratio-1.94
P/B Ratio7.40
P/S Ratio19.83
EPS (TTM)$0.00
52-Week High$9.19
52-Week Low$1.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-433.33%
ROA-40.62%
ROCE-700.00%
Gross Margin-1400.00%
Operating Margin-1400.00%
Net Margin-10.39%
Debt/Equity9.78
Current Ratio1.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$10.0M$3.0M$0$1.0M
Operating Profit$-39.0M$-31.0M$-31.0M$-23.0M$-14.0M
Net Profit$-39.0M$-31.0M$-30.0M$-4.0M$-13.0M
EPS$-7.52$-4.39$-4.15$-0.48$-1.20
Op Margin—-313.9%-1101.9%-239692.2%-1315.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$56.0M$44.0M$21.0M$22.0M$32.0M
Total Liabilities$17.0M$33.0M$26.0M$28.0M$30.0M
Cash$52.0M$35.0M$10.0M$16.0M$25.0M
Borrowings$0$0$1.0M$1.0M$3.0M

Latest News

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities GlobeNewswire · Jul 20, 2026 Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event GlobeNewswire · Jul 9, 2026 Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform GlobeNewswire · Jul 1, 2026 Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment GlobeNewswire · Jun 25, 2026 Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 GlobeNewswire · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-29.0M$-18.0M$-39.0M$5.0M$-9.9B
Investing Cash Flow$0$0$-1.0M$-1.0M$-771.0M
Financing Cash Flow$1.0M$0$6.0M$0$19.3B
Net Cash Flow$47.0M$-17.0M$-24.0M$5.0M$9.0B
Free Cash Flow$-29.0M$-18.0M$-39.0M$5.0M$-10.3B

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-44.29%
Quick Ratio1.03
Interest Coverage-14.00
Return 1Y-27.11%
Return 3Y-80.17%
Return 5Y-88.27%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADTX $0.01 -77.22% -0.01 $318 0.00%
AIMD $1.49 -3.87% -0.43 $10.97M 0.00%
ANLAdlai Nortye Ltd. $13.26 +2.00% -8.19 $703.84M 0.00%
ASBP $7.26 +3.13% -0.74 $837601 0.00%
ATHAAthira Pharma, Inc. $6.75 -6.12% -0.28 $26.62M 0.00%

About DARE

DARE is led by CEO Sabrina Martucci Johnson, employs 21 people, headquartered in US, publicly traded since 2014.

DARE stock trades at $1.32 with a market capitalization of $12.57M. The stock is valued at a price-to-earnings (P/E) ratio of -1.94, price-to-book of 7.40, price-to-sales of 19.83. Over the past 52 weeks the stock has ranged between $1.17 and $9.19, and currently trades 85.6% below its 52-week high.

On profitability, DARE generates a return on equity (ROE) of -433.33%, return on capital employed of -700.00%, an operating margin of -1400.00%, a net profit margin of -10.39%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides